This ongoing study will further evaluate long-term survival outcome, testifying to the role of tumor-informed MRD detection during the perioperative period and verifying the value of pretreatment immune phenotype in selecting potential beneficiaries of immunotherapy in EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is neoplasm.